xmlns:o="urn:schemas-microsoft-com:office:office"
xmlns:w="urn:schemas-microsoft-com:office:word"
xmlns:st1="urn:schemas-microsoft-com:office:smarttags"
xmlns="http://www.w3.org/TR/REC-html40">
http://www.observer.co.uk/uk_news/story/0,6903,363705,00.html
Meningitis
advisers funded by drug firms
Fresh controversy surrounding Britain's
Meningitis C vaccination programme
Martin Bright and Tracy
McVeigh
Sunday September 3, 2000
The Observer
Four of the medical experts advising the Government on whether the new
meningitis C vaccine is safe have links to one or more of the drug companies
that produce it, The Observer has discovered. The revelations,
following last week's report of a cover-up of suspected adverse reactions to
the drug, has prompted concern among parents and MPs about conflicts of
interest in the medical profession.
The Department of Health
last night confirmed that Professor Janet Darbyshire,
a member of the Government's Committee on Safety of Medicines, had received
support for academic research from US firms Wyeth
and Chiron, who produce the two main meningitis products being used on children
in Britain: Meningitec
and Meninjugate. Darbyshire
is professor of epidemiology at London University and director of the Medical
Research Council.
DoH officials also confirmed that three
members of the Joint Committee on Vaccination and Immunisation
had declared interests in vaccine manufacturers.
One of them, Dr David Goldblatt of the Institute of Child Health, has served on
an expert advisory panel for Wyeth and received
research grants from Wyeth and North American
Vaccines, which produces a third meningitis C drug to be introduced this year.
Another, Professor Keith Cartwright of the University of Bristol, received funding from the drug
industry to 'evaluate candidate meningicoccal
vaccines'.
Exposure of the links
between the advisers and drugs firms came as the Government's Chief Medical
Officer reacted strongly to last week's Observer story of how information on
possible adverse reactions to the vaccine was kept from parents. In a letter to
The Observer, published today, Professor Liam Donaldson insists information on
reactions to vaccinations is sent, on request, to members of the public, health
professionals or MPs by the Medicines Con trol
Agency. 'There is not, and never has been, a "cover-up" over
releasing information about reported deaths or suspected adverse reactions
following meningitis C vaccine,' he said.
This week every GP in the
country will receive a statement from the chairs of the two committees,
assuring them of the safety of the meningitis C vaccine. The statement, from
Professor Alasdair Breckenridge of the Committee on Safety of Medi cines, and Professor Michael Langman
of the Joint Committee on Vaccination and Immunisation,
updates information made public by The Observer last weekend about bad
reactions to the new vaccine reported by GPs and nurses. It says there have
been 16,527 reported adverse reactions from 7,742 patients, and 12 deaths. It
reiterates that none of the deaths reported by GPs was found to be connected to
the vaccine.
The statement ends: 'The
balance of risk and benefit is overwhelmingly favourable.
There is no suggestion that this vaccine has led to any deaths. We strongly
recommend that those due for vaccination should receive meningitis C vaccine.'
Latest figures show that
more than 15 million doses of the meningitis C vaccine have been give to
children and teenagers in the past 10 months.
Statistics from the Public
Health Laboratory Service show that, in the 15-to-17-year-old group, in the
last 12 weeks only six cases of meningitis were reported, compared with 26 in
the same period last year. And in children under one year old, there was only one
case reported in this period, compared with 19 in 1999.
Incidences of meningitis
continue to rise in those who have not been vaccinated.
Despite assurances that
information on possible adverse reactions to the vaccine is freely available,
parents calling the Medicines Control Agency told The Observer they were still
being refused the data.
In north Somerset, one mother of a 13-year-old was
told 'it wasn't necessary' for her to have that information.
'My son is about to have
his vaccination and, after reading last week's Observer that figures on adverse
reactions existed, I wanted to see them. I believe I have a right as a mother
to have all the information to hand when I make a decision,' she said. She said
the agency employee had told her: 'Stories like this should really be taken cum
grano salis - that's a
pinch of salt in English, madam.'
Another caller was told
that the MCA did not have the information and referred her to her doctor. A
third caller eventually managed to get a copy of the letter sent to GPs.
The figures collated by the
agency are based on the 'yellow card reporting scheme'. This seeks reports of
suspected adverse reactions to drugs from health professionals. They are
requested to submit reports of reactions whether or not it is clear that a drug
or vaccine caused it. The 12 deaths reported under this scheme may be an
underestimation, since only around 15 per cent of GPs and healthcare
professionals use the yellow card scheme. The Department of Health believes
that the reporting rate is higher where a new drug is involved.
The Liberal Democrat
consumer affairs spokesman, Norman Baker, has tabled parliamentary questions
about the financial interests of members of Department of Health advisory
committees. He said last night: 'This is a question of propriety. There must be
enough independent people around to give advice without turning to those who
clearly have a conflict of interests. I am not questioning their academic
credentials, but with the best will in the world their judgments must be looked
at in that context.'
Tory Health spokesman Liam
Fox, a GP, said the Government must reassure the public.
The Secretary of State authorised the licence for the Wyeth vaccine, Meningitec, when
the mass immunisation programme
began last November, on advice from the Committee on Safety of Medicines. The
Joint Committee on Vaccination and Immunisation also
recommended the vaccine.
Wyeth spokesman Don Barrett said the
amount of money paid to the academic departments of government committee members
was confidential. Chiron, whose vaccine was introduced in April, stands to make
$200 million from the NHS deal.
Last night the National
Meningitis Trust, sponsored by Wyeth, was drawn into
the controversy when it refused to disclose how much money it received from the
giant drug company. In a statement, Chief Executive Philip Kirby said: 'We would refute in the strongest possible terms the
suggestion that any information we provide is anything other than totally
objective and the best available.'
This week Posh Spice
Victoria Beckham revealed she had viral meningitis, a less serious type of the
disease. After doctors ordered her to rest, she cancelled several appearances
and flew home from Germany. Viral meningitis is an
inflammation of the lining of the brain and usually clears up within a week or
two without treatment.
ALL
INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR
GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE
KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED
AS PROVIDING MEDICAL OR LEGAL ADVICE. THE DECISION WHETHER OR NOT TO
VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU
ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.